oAlert.pl

Recalled Medicines & supplements – Current GIS Alerts 2026

Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.

Common hazards in this category

All recalled products

Pasta borowinowa lecznicza – recalled product

Pasta borowinowa lecznicza

CRITICAL 28.07.2023

An excessive amount of Clostridium perfringens and the presence of Candida farmata/guilliermondii yeasts were detected, meaning the product does not meet microbiological purity requirements and may pose a health risk to patients when applied to the skin. Potential effects: skin infections, irritation, complications in immunocompromised individuals.

Tresuvi – recalled product

Tresuvi

CRITICAL 24.07.2023

Unidentified solid particles were detected in the solution for infusion; due to the unknown nature of the contamination, a risk to patients’ health and life cannot be excluded. Potential effects: thrombotic complications, emboli, inflammatory reactions, life-threatening events.

Andepin – recalled product

Andepin

MEDIUM 24.07.2023

Due to the detected increased content of a single impurity, a health risk for the patient taking this product cannot be excluded. Potential effects: poisoning, increased adverse reactions, complications of therapy.

Autostrzykawka Morfina Przeciwko Bólowi – recalled product

Autostrzykawka Morfina Przeciwko Bólowi

CRITICAL 18.07.2023

Due to the detected solution discoloration that does not comply with quality requirements, the risk to the patient’s health and life cannot be excluded. Potential effects: poisoning, severe adverse reactions, life-threatening complications.

Sirdalud MR – recalled product

Sirdalud MR

HIGH 07.07.2023

It is not possible to guarantee specification-compliant active substance release after 2 hours until the end of the shelf-life, which may affect the quality and safety of product use. Potential effects: lack of treatment efficacy or increased adverse effects.

Sirdalud MR – recalled product

Sirdalud MR

MEDIUM 07.07.2023

It is not possible to guarantee specification-compliant release of tizanidine hydrochloride after 2 hours, and the cause is not fully understood, so the impact on product quality and safety of use cannot be predicted. Potential effects: lack of treatment efficacy or adverse effects related to incorrect dosing.

Detimedac 200 mg – recalled product

Detimedac 200 mg

CRITICAL 03.07.2023

The pink discoloration may be caused by degradation of the active substance, which may pose an increased risk to the patient. Potential effects: lack of treatment efficacy, complications of oncological therapy, possible adverse effects related to degradation products.

Detimedac 500 mg – recalled product

Detimedac 500 mg

CRITICAL 03.07.2023

The pink discoloration may be caused by degradation of the active substance, which may pose an increased risk to the patient. Potential effects: lack of treatment efficacy, possible adverse reactions.

Detimedac 100 mg – recalled product

Detimedac 100 mg

CRITICAL 03.07.2023

Pink discoloration may be caused by degradation of the active substance, which may represent an increased risk to the patient. Potential effects: reduced treatment efficacy or unpredictable adverse reactions.

Lorabex – recalled product

Lorabex

CRITICAL 29.06.2023

It was suspected that the product might not meet quality requirements (out-of-specification results for lorazepam content and related substances), but testing of samples taken from the market confirmed correct quality of the batch. Potential effects: possible alteration of drug action, lack of efficacy or adverse effects.

Mebelin – recalled product

Mebelin

MEDIUM 26.06.2023

Due to the reduced values of active substance release in the product, the risk to patient health resulting from decreased drug efficacy cannot be excluded. Potential effects: lack of treatment efficacy, possible worsening of disease symptoms.

PALIFREN LONG – recalled product

PALIFREN LONG

MEDIUM 16.06.2023

A reduced content of the active substance paliperidone palmitate and an increased particle size compared to requirements were found, which may lead to reduced medicinal efficacy and a risk to patient health. Potential effects: reduced treatment efficacy, worsening of disease symptoms.

Duracef – recalled product

Duracef

MEDIUM 14.06.2023

Testing showed a lower value of cefadroxil release within 30 minutes, so a risk to patient health due to lack of drug efficacy cannot be excluded. Potential effects: lack of treatment effectiveness, possible disease complications.

APAP dla dzieci FORTE – recalled product

APAP dla dzieci FORTE

MEDIUM 26.05.2023

The suspension in the bottle contained gas bubbles, was foamed, had increased volume, and in several cases was non-uniform and separated into layers, which may indicate a significant quality defect of the medicine. Potential effects: incorrect dosing, reduced effectiveness, possible adverse reactions.

Tirosint Sol – recalled product

Tirosint Sol

HIGH 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: lack of efficacy in treating thyroid disorders, worsening of health status, possible complications of concomitant diseases.

Tirosint Sol – recalled product

Tirosint Sol

HIGH 27.04.2023

A probability of reduced content of the active substance – levothyroxine sodium – was identified in some batches, which may lead to insufficient treatment efficacy. Potential effects: lack of thyroid disease control, complications, worsened well-being.

Tirosint Sol – recalled product

Tirosint Sol

HIGH 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health from decreased drug effectiveness cannot be excluded. Potential effects: lack of treatment efficacy, complications of the underlying disease.

Tirosint Sol – recalled product

Tirosint Sol

HIGH 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: reduced treatment efficacy, possible worsening of thyroid disease symptoms.

Tirosint Sol – recalled product

Tirosint Sol

HIGH 27.04.2023

Due to the probability of reduced active substance content in the product, the risk to patient health resulting from decreased effectiveness of the medicine cannot be excluded. Potential effects: ineffective treatment, worsening of disease symptoms, complications resulting from thyroid hormone deficiency.

Tirosint Sol – recalled product

Tirosint Sol

MEDIUM 27.04.2023

A probability of reduced content of the active substance – levothyroxine sodium – was identified, which prevents guaranteeing proper medicinal quality and may lead to reduced therapeutic efficacy. Potential effects: reduced treatment effectiveness, risk of exacerbation of thyroid disease symptoms.

What to do if you bought a recalled product?

If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.